CLIA (Clinical Laboratory Improvement Amendments) — Lexicon of the Business of Modern Medicine™

Laboratory & Diagnostics

CLIA (Clinical Laboratory Improvement Amendments)

10 min readLast reviewed: June 2025AJ Pakpour, Healthcare Practice Startup & Strategy Expert
CLIAlaboratory complianceCLIA waiverin-office lablaboratory certification

Definition

CLIA (Clinical Laboratory Improvement Amendments) is the federal law and regulatory framework that establishes quality standards for all laboratory testing performed on human specimens in the United States, administered by CMS and enforced through a certificate-based system with five certificate types based on test complexity.

Comprehensive Definition

The Clinical Laboratory Improvement Amendments (CLIA) of 1988 established a comprehensive federal regulatory framework for laboratory testing performed on human specimens for the purpose of diagnosis, prevention, or treatment of disease. CLIA applies to virtually every facility that performs laboratory testing on human specimens — including hospitals, independent laboratories, physician office laboratories, clinics, nursing homes, and even some point-of-care testing sites. The law is codified at 42 U.S.C. 263a and implemented through regulations at 42 CFR Part 493, administered by the Centers for Medicare & Medicaid Services (CMS) in collaboration with the CDC and FDA.

CLIA establishes quality standards across three areas: personnel qualifications, quality control, and proficiency testing. The specific requirements that apply to a laboratory depend on the complexity of the tests it performs. CLIA categorizes laboratory tests into three complexity levels: waived, moderate complexity, and high complexity. The FDA is responsible for categorizing each test into one of these complexity levels based on the risk of an incorrect result and the difficulty of performing the test correctly.

There are five types of CLIA certificates, each authorizing different levels of testing:

Certificate of Waiver (CoW): Authorizes performance of only CLIA-waived tests — simple tests with a low risk of error, such as urine dipstick, blood glucose monitoring, rapid strep tests, and certain rapid influenza tests. The CoW has minimal regulatory requirements and is the easiest certificate to obtain. Application is submitted to the state agency, and the fee is $150 for a two-year certificate.

Certificate for Provider-Performed Microscopy (PPM): Authorizes waived tests plus a specific list of microscopy procedures performed by a physician, midlevel practitioner, or dentist during a patient visit. PPM procedures include wet mounts, KOH preparations, pinworm examinations, fern tests, and post-coital direct qualitative examinations of vaginal or cervical mucus.

Certificate of Registration: A temporary certificate issued while a laboratory awaits inspection for a Certificate of Compliance or Certificate of Accreditation. It authorizes moderate and high-complexity testing during the interim period.

Certificate of Compliance: Authorizes moderate and high-complexity testing. Requires a CMS or state agency inspection and ongoing compliance with all applicable CLIA requirements, including personnel qualifications, quality control, proficiency testing, and quality assurance.

Certificate of Accreditation: Authorizes moderate and high-complexity testing for laboratories accredited by a CMS-approved accreditation organization (such as CAP or COLA). Accreditation by an approved organization is deemed to satisfy CLIA requirements, and the laboratory is inspected by the accreditation organization rather than CMS.

CLIA applications are submitted to the state agency in the state where the laboratory is located. The CMS CLIA website (cms.gov/clia) provides state agency contact information, application forms, and fee schedules.

Why It Matters

CLIA compliance is not optional — it is a federal legal requirement for any facility that performs laboratory testing on human specimens. Performing laboratory testing without the appropriate CLIA certificate is a federal violation that can result in civil monetary penalties, exclusion from Medicare and Medicaid, and in serious cases, criminal prosecution. CMS has the authority to impose penalties of up to $10,000 per day of violation and to revoke a laboratory's CLIA certificate.

For practice operators, understanding CLIA is essential before adding any in-office laboratory testing capability. The most common mistake is assuming that a Certificate of Waiver covers all the tests a practice wants to perform. Many tests that seem simple — including most PCR-based molecular tests, most immunoassay-based drug testing panels, and most flow cytometry tests — are not waived and require a Certificate of Compliance or Accreditation. Performing these tests under a Certificate of Waiver is a CLIA violation.

CLIA compliance also affects reimbursement. Medicare and Medicaid will not reimburse laboratory tests performed by a laboratory that does not have the appropriate CLIA certificate. Payers routinely verify CLIA certification status as part of their credentialing and claims review processes. A laboratory that loses its CLIA certificate — or that never had the appropriate certificate for the tests it was performing — faces not only regulatory penalties but also recoupment of payments received for non-compliant testing.

Historical Background

CLIA was enacted in 1988 in response to concerns about the quality of laboratory testing in the United States, particularly in physician office laboratories and other non-hospital settings. A series of investigative reports in the 1980s documented significant quality problems in laboratory testing, including high rates of false-positive and false-negative results, inadequate quality control, and unqualified personnel performing complex tests.

The original CLIA of 1967 had applied only to laboratories that crossed state lines with their specimens. The 1988 amendments dramatically expanded the scope of federal laboratory regulation to cover virtually all clinical laboratories, regardless of size or location. The implementing regulations were published in 1992 and have been updated periodically since then to reflect advances in laboratory technology and changes in the test complexity landscape.

The CLIA waiver category was created to reduce the regulatory burden on facilities performing simple, low-risk tests. The Balanced Budget Act of 1997 expanded the waiver category and directed FDA to develop criteria for waiving tests that are simple to perform and have a low risk of error. Since then, the number of waived tests has grown substantially, and many point-of-care tests that were previously moderate complexity have been reclassified as waived following FDA review.

Federal Regulations

CLIA is codified at 42 U.S.C. 263a and implemented through regulations at 42 CFR Part 493. Key subparts of 42 CFR Part 493 include:

Subpart A — General Provisions (definitions, applicability) Subpart B — Certificate Requirements (certificate types, application procedures) Subpart C — Fees (certificate fees by certificate type and test volume) Subpart D — Inspections (inspection authority, frequency, procedures) Subpart H — Participation in Proficiency Testing (PT requirements by specialty) Subpart J — Patient Test Management (pre-analytic, analytic, post-analytic requirements) Subpart K — Quality Control (QC requirements by complexity level) Subpart M — Personnel (qualifications for laboratory director, technical supervisor, clinical consultant, testing personnel) Subpart P — Quality Assurance (QA program requirements) Subpart Q — Inspections (inspection procedures and sanctions) Subpart R — Enforcement Procedures (sanctions, civil monetary penalties)

CMS administers CLIA in partnership with the CDC (which provides technical assistance and proficiency testing oversight) and FDA (which categorizes test complexity). State agencies may also have authority to conduct CLIA inspections and impose additional state-level laboratory requirements.

State Considerations

Several states have enacted laboratory licensing requirements that are more stringent than CLIA and require separate state licensure in addition to CLIA certification. States with their own laboratory licensing programs include California, Florida, Georgia, Hawaii, Illinois, Maryland, Michigan, Nevada, New Jersey, New York, North Carolina, Pennsylvania, Rhode Island, Tennessee, Washington, and West Virginia. New York State has particularly comprehensive laboratory oversight through the Clinical Laboratory Evaluation Program (CLEP), which requires separate approval for each test performed.

State laboratory licensing requirements vary significantly in their scope, application procedures, fees, and inspection processes. Practices planning to perform laboratory testing should verify their state's specific requirements before applying for CLIA certification.

Common Mistakes

  • Performing moderate or high-complexity tests (including most PCR, immunoassay drug panels, and molecular tests) under a Certificate of Waiver.
  • Failing to apply for CLIA certification before performing any laboratory testing — even a single test requires a certificate.
  • Not maintaining required quality control records, proficiency testing enrollment, and personnel documentation for the certificate type held.
  • Allowing unqualified personnel to perform testing — CLIA has specific education and experience requirements for testing personnel at each complexity level.
  • Failing to update the CLIA certificate when adding new tests that exceed the complexity level authorized by the current certificate.
  • Not responding to CLIA inspection findings within the required timeframe, which can result in escalating sanctions.

Operator Insight

CLIA is one of the most misunderstood regulatory frameworks I encounter when working with startup clinics. The most common misconception is that a Certificate of Waiver covers everything a practice wants to do in the office. It does not. A Certificate of Waiver only covers tests on the FDA's waived test list — and that list does not include most of the high-value tests that practices want to add, including most PCR panels, most immunoassay drug testing panels, and most molecular diagnostics. Before you add any in-office testing, go to the FDA's CLIA database and look up the specific test you want to perform. Find out its complexity classification. If it is waived, a Certificate of Waiver is sufficient. If it is moderate or high complexity, you need a Certificate of Compliance or Accreditation — and that means meeting personnel requirements, implementing quality control programs, enrolling in proficiency testing, and passing an inspection. For practices that want to add high-complexity testing, I generally recommend pursuing CAP or COLA accreditation rather than a Certificate of Compliance. Accreditation provides a structured framework for building a compliant laboratory, ongoing education and support from the accreditation organization, and a recognized quality credential that can be valuable for payer credentialing and patient trust. The investment in accreditation is almost always worth it for practices that are serious about building a sustainable laboratory program.

— AJ Pakpour, Healthcare Practice Startup & Strategy Expert

In Practice

A family medicine practice in Ohio wanted to add in-office urine drug testing and rapid strep testing. They verified that the specific tests they wanted to perform were on the FDA's waived test list, applied for a Certificate of Waiver, and received their certificate within three weeks. Their total cost was $150 for the two-year certificate plus the cost of the testing equipment and supplies. They were performing waived tests within 30 days of deciding to add in-office testing. A sexual health clinic in California wanted to add high-complexity STI PCR panels to their in-office capabilities. They applied for a Certificate of Accreditation through COLA, hired a qualified laboratory director, implemented a quality control program, enrolled in proficiency testing, and passed their initial COLA inspection within four months. The process required significant upfront investment in personnel, equipment, and compliance infrastructure, but enabled them to perform high-complexity molecular testing in-house and capture the associated reimbursement.

Frequently Asked Questions

References

  1. 1.CMS — CLIA Program Overview
  2. 2.42 CFR Part 493 — Laboratory Requirements
  3. 3.CDC — CLIA Overview
  4. 4.FDA — CLIA Waived Tests Database
  5. 5.CMS — CLIA Certificate Application (CMS-116)

Further Reading

Recommended Professional References

The following authoritative resources are recommended for healthcare professionals, clinic owners, compliance officers, and entrepreneurs working in this area. Links open official external websites.

CMS

Federal program resources.

Federal policyFree

Best for: Practice leaders

HHS OIG

Compliance resources.

ComplianceFree

Best for: Compliance teams

FSMB

Medical regulation resources.

RegulationFree

Best for: Clinical leaders

AMA

Practice resources.

GuidanceFree + Paid

Best for: Medical practices

Turn Knowledge Into Action

Apply what you just learned. Book a strategy session with AJ Pakpour — healthcare practice startup and strategy expert.

Book a Strategy Session